tetano
Editor, Senior Moderator
Sci Rep
. 2024 May 28;14(1):12217.
doi: 10.1038/s41598-024-62044-9. PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients
Giuseppe Castellano[SUP] 1 2 [/SUP], Giuseppe Stefano Netti[SUP] 3 [/SUP], Vincenzo Cantaluppi[SUP] 4 [/SUP], Vincenzo Losappio[SUP] 5 [/SUP], Federica Spadaccino[SUP] 3 [/SUP], Elena Ranieri[SUP] 3 [/SUP], Marita Marengo[SUP] 6 [/SUP], Maurizio Borzumati[SUP] 7 [/SUP], Carlo Alfieri[SUP] 8 9 [/SUP], Giovanni Stallone[SUP] 5 [/SUP]
Affiliations
Patients on hemodialysis (HD) have a high risk of death from COVID-19. We evaluated the humoral and cell-mediated immune response to BNT162b2 (Pfizer-BioNTech) vaccine in HD patients, comparing HD with Poly-methyl-methacrylate (PMMA) and HD with Polysulphone (PS). Samples were collected before vaccination (T0) and 14-days after the 2ndvaccine (T2) in a TG (TG, n = 16-Foggia) and in a VG (CG, n = 36-Novara). Anti-SARS-CoV-2-Ig were titrated in the cohort 2-weeks after the 2nddose of vaccine. In the Testing-Group, serum neutralizing antibodies (NAb) were assayed and PBMCs isolated from patients were thawed, counted and stimulated with SARS-CoV-2 IGRA stimulation tube set. All patients had a positive ab-response, except in a case. PMMA-patients had higher levels of anti-SARS-CoV-2 IgG (p = 0.031); VG data confirmed these findings (p < 0.05). NAb evaluation: PMMA patients passed the positive cut-off value, while in PS group only only 1/8 patient did not respond. PMMA patients showed higher percentages of anti-SARS-CoV-2 S1/RBD-Ig after a complete vaccine schedule (p = 0.028). Interferon-gamma release: PMMA patients showed significantly higher release of IFNγ (p = 0.014). The full vaccination course provided sufficient protection against SARS-CoV-2 across the entire cohort, regardless of dialyzer type. After vaccination, PMMA patients show a better immune response, both humoral and cellular, at the end of the vaccination course than PS patients.
Keywords: Cellular immunity; Hemodialysis patients; Humoral immunity; Poly-methyl-methacrylate; SARS-CoV-2 vaccination; Vaccine antibody response.
. 2024 May 28;14(1):12217.
doi: 10.1038/s41598-024-62044-9. PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients
Giuseppe Castellano[SUP] 1 2 [/SUP], Giuseppe Stefano Netti[SUP] 3 [/SUP], Vincenzo Cantaluppi[SUP] 4 [/SUP], Vincenzo Losappio[SUP] 5 [/SUP], Federica Spadaccino[SUP] 3 [/SUP], Elena Ranieri[SUP] 3 [/SUP], Marita Marengo[SUP] 6 [/SUP], Maurizio Borzumati[SUP] 7 [/SUP], Carlo Alfieri[SUP] 8 9 [/SUP], Giovanni Stallone[SUP] 5 [/SUP]
Affiliations
- PMID: 38806543
- PMCID: PMC11133365
- DOI: 10.1038/s41598-024-62044-9
Patients on hemodialysis (HD) have a high risk of death from COVID-19. We evaluated the humoral and cell-mediated immune response to BNT162b2 (Pfizer-BioNTech) vaccine in HD patients, comparing HD with Poly-methyl-methacrylate (PMMA) and HD with Polysulphone (PS). Samples were collected before vaccination (T0) and 14-days after the 2ndvaccine (T2) in a TG (TG, n = 16-Foggia) and in a VG (CG, n = 36-Novara). Anti-SARS-CoV-2-Ig were titrated in the cohort 2-weeks after the 2nddose of vaccine. In the Testing-Group, serum neutralizing antibodies (NAb) were assayed and PBMCs isolated from patients were thawed, counted and stimulated with SARS-CoV-2 IGRA stimulation tube set. All patients had a positive ab-response, except in a case. PMMA-patients had higher levels of anti-SARS-CoV-2 IgG (p = 0.031); VG data confirmed these findings (p < 0.05). NAb evaluation: PMMA patients passed the positive cut-off value, while in PS group only only 1/8 patient did not respond. PMMA patients showed higher percentages of anti-SARS-CoV-2 S1/RBD-Ig after a complete vaccine schedule (p = 0.028). Interferon-gamma release: PMMA patients showed significantly higher release of IFNγ (p = 0.014). The full vaccination course provided sufficient protection against SARS-CoV-2 across the entire cohort, regardless of dialyzer type. After vaccination, PMMA patients show a better immune response, both humoral and cellular, at the end of the vaccination course than PS patients.
Keywords: Cellular immunity; Hemodialysis patients; Humoral immunity; Poly-methyl-methacrylate; SARS-CoV-2 vaccination; Vaccine antibody response.